Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver) (NCT07665372)
HOPE in Action Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to better understand opportunistic infections and cancer in transplant recipients with HIV who receive livers from a donor with HIV compared to livers from donors without HIV.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic, Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- HIV D+/R+ (OTHER)
- HIV D-/R+ (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Mayo Clinic, Arizona — Phoenix, Arizona
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- University of Colorado Anschutz — Aurora, Colorado
- Mayo Clinic, Florida — Jacksonville, Florida
- University of Miami, Miami Transplant Institute — Miami, Florida
- Emory University — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Ochsner Clinic Foundation — Jefferson, Louisiana
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- New York University School of Medicine — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Weill Cornell Medical College — New York, New York
- University of Cincinnati — Cincinnati, Ohio
- Ohio State University Medical Center — Columbus, Ohio
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- University of Texas Southwestern Medical Center — Dallas, Texas
- Houston Methodist Research Institute — Houston, Texas
📞 Contact the Study Coordinator
Phone: (410) 614-6702
Email: ChristineDurand@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV
- CD4 CAR+ ZFN-modified T Cells in HIV Therapy — Philadelphia, Pennsylvania
- Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP — Orlando, Florida
- Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients — Duarte, California
- Urban Gardening and Peer Nutritional Counseling for People With HIV and Food Insecurity — Azua,
- Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. — Birmingham, Alabama
- Wellness, Intervention Strategies and HIV Care — Oakland, California
Explore by condition: All HIV clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.